Skip to main content


Fig. 5 | Diabetology & Metabolic Syndrome

Fig. 5

From: Coadministration of DPP-4 inhibitor and insulin therapy does not further reduce the risk of cardiovascular events compared with DPP-4 inhibitor therapy in diabetic foot patients: a nationwide population-based study

Fig. 5

Cox proportional hazard regression analyses were performed for subgroups of patients with respect to the primary MACE outcome (including nonfatal myocardial infarction, nonfatal stroke, cardiac death, and heart failure). P values signify the differences between groups. CI confidence interval, ESRD end-sage renal disease, MACE major adverse cardiac event, DPP4 dipeptidyl peptidase-4

Back to article page